Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 11/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 11/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3085985 | 0.91 | CHRM5 (0.41) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL7026727 | 0.86 | PPARG (0.41) | CHRM5CHRM1P2RX3ESR2NR1H2 | |
| SCHEMBL5942308 | 0.83 | CHRM5 (0.42) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL5276073 | 0.82 | REN (0.38) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL5942248 | 0.81 | CHRM5 (0.39) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL6169162 | 0.79 | REN (0.40) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL951850 | 0.78 | ESR2 (0.48) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL25262018 | 0.77 | ESR2 (0.45) | CHRM5CHRM1ESR2NR1H2HDAC1 | |
| SCHEMBL952114 | 0.77 | ESR2 (0.45) | CHRM5CHRM1ESR2NR1H2HDAC1 | |
| SCHEMBL3044833 | 0.77 | CHRM5 (0.43) | CHRM5CHRM1CHRM2CHRM4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324052-A1 | NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES | BEZENCON OLIVIER | 2010-12-23 | — | — | US | disclosed |
| US-7799805-B2 | Piperidine carboxylic acid amide derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | REN, ACE, AGTR2 | CHRM5 2088/4885CHRM1 1965/4885CHRM2 1927/4885 |
| US-20100324052-A1 | NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES | REN, ACE, AGTR2 | CHRM5 1292/4885CHRM1 1234/4885CHRM2 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.